Evaluating Claudin-6 and isochromosome 12p in the progression from germ cell neoplasia in situ to primary testicular germ cell tumor and post-chemotherapy teratoma: implications for CLDN6-targeted therapies
Therapeutic Advances in Medical Oncology
Published online on March 14, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Despite advancements in treatment of advanced testicular germ cell tumors (GCT), metastatic teratoma remains a significant challenge due to its intrinsic chemo- and radioresistance. Claudin-6 (CLDN6), a tumor-specific antigen, has shown promise ...
Background:Despite advancements in treatment of advanced testicular germ cell tumors (GCT), metastatic teratoma remains a significant challenge due to its intrinsic chemo- and radioresistance. Claudin-6 (CLDN6), a tumor-specific antigen, has shown promise ...